Fred Saad

Fred Saad

2900 Edouard Montpetit Blvd
Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1011 publications

ASO Visual Abstract: Cancer-Specific Mortality in Rare Histologic Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy.

ASO Visual Abstract: Cancer-Specific Mortality in Rare Histologic Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy.

Journal: Annals of surgical oncology

Published: September 07, 2026

Managing Metabolic Syndrome and Prostate Cancer.

Managing Metabolic Syndrome and Prostate Cancer.

Journal: JAMA oncology

Published: August 13, 2026

ASO Visual Abstract: Risk-adapted use of adjuvant systemic therapy after nephrectomy for renal cell carcinoma: a population-based study in the post-approval era.

ASO Visual Abstract: Risk-adapted use of adjuvant systemic therapy after nephrectomy for renal cell carcinoma: a population-based study in the post-approval era.

Journal: Annals of surgical oncology

Published: August 10, 2026

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2026

ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care.

ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care.

Journal: Annals of surgical oncology

Published: July 30, 2026

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Journal: Future oncology (London, England)

Published: July 06, 2026

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Journal: Future oncology (London, England)

Published: June 19, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Journal: Future oncology (London, England)

Published: June 09, 2026

ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.

ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.

Journal: Annals of surgical oncology

Published: June 08, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era.

Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era.

Journal: Annals of surgical oncology

Published: May 28, 2026

Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.

Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.

Journal: BMJ open

Published: May 28, 2026

Showing 1-12 of 1,011

Last Updated: 09/26/2026